ERBB2 and ampulla of vater adenocarcinoma: This pioneering study is the first to examine recurrence and survival outcomes in relation to druggable alterations (EGFR, HER2, and c-Met overexpression) among surgically resected ampullary adenocarcinoma patients at risk of recurrence, excluding very early-stage cases.